A Meta-analysis of the Incidence and Risk of Skin Toxicity with Nab-paclitaxel and Paclitaxel in Cancer Treatment

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2023 Jul 12

PMID 37434856

Authors

Hong-Bo Li

Wen-Hui Wang

Zhi-Yong Wang

Affiliations

Soon will be listed here.

Abstract

Background: Skin toxicity of varying severity occurs mostly during various courses of chemotherapy. In clinical trials and practice, we have found that both nab-paclitaxel and paclitaxel cause side effects such as rash and pruritus. To further clarify the incidence of rash and pruritus in both, we conducted the present study by a systematic evaluation, the results of which can be used to guide clinical dosing choices.

Methods: An electrical search was performed on randomized controlled research trials of nab-paclitaxel and paclitaxel for the treatment of malignancies. The necessary data were extracted, integrated, and analyzed from the included studies by systematic evaluation and meta-analysis, depending on the study design. Further subgroup analyses were performed to explore the incidence of rash and pruritus in nab-paclitaxel and paclitaxel.

Results: Eleven studies with a total of 971 patients with malignancy were included. Four studies were application of single-agent nab-paclitaxel compared with paclitaxel, and seven studies were comparative chemotherapy drug combinations. The incidence of rash was higher in all grades of nab-paclitaxel than that in paclitaxel (OR=1.39, CI 95% [1.18-1.62]); the incidence of rash was higher in lower grades of paclitaxel than that in solvent-based paclitaxel (OR=1.31, CI 95% [1.11-1.53]); the incidence of rash was higher in all grades in the single-agent application comparison. The incidence of rash was higher in nab-paclitaxel than that in paclitaxel (OR=1.81, CI 95% [1.26-2.59]); there was no significant difference in the incidence of pruritus between nab-paclitaxel and paclitaxel (OR=1.19, CI 95% [0.88-1.61]).

Conclusion: In comparison with paclitaxel, nab-paclitaxel significantly increased the risk of a teething rash. There was a significant risk correlation between nab-paclitaxel and teething rash. Early prevention, identification, and treatment of rash could significantly improve patient's quality of life and optimize their clinical survival.

Citing Articles

Proteomic analysis of dorsal root ganglia in a mouse model of paclitaxel-induced neuropathic pain.

Hanna R, Graur A, Sinclair P, Mckiver B, Bos P, Damaj M PLoS One. 2024; 19(9):e0306498.

PMID: 39331687 PMC: 11432834. DOI: 10.1371/journal.pone.0306498.

Incidence and prognosis of taxane-induced macular edema: a retrospective study from the Japan Clinical REtina Study Group (J-CREST).

Tsujinaka H, Imoto S, Ueda T, Wakuta M, Yamada Y, Sugisawa T Sci Rep. 2024; 14(1):19530.

PMID: 39174604 PMC: 11341814. DOI: 10.1038/s41598-024-69775-9.

Proteomic Analysis of Dorsal Root Ganglia in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.

Hanna R, Graur A, Sinclair P, Mckiver B, Paula D Bos M, Damaj M bioRxiv. 2024; .

PMID: 38979383 PMC: 11230256. DOI: 10.1101/2024.06.20.599888.

Keratinocyte Piezo1 drives paclitaxel-induced mechanical hypersensitivity.

Mikesell A, Isaeva E, Schulte M, Menzel A, Sriram A, Prahl M bioRxiv. 2024; .

PMID: 38168305 PMC: 10760029. DOI: 10.1101/2023.12.12.571332.

References

Gradishar W, Krasnojon D, Cheporov S, Makhson A, Manikhas G, Clawson A . Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer. 2012; 12(5):313-21. DOI: 10.1016/j.clbc.2012.05.001. View

Stravodimou A, Voutsadakis I . Hand and foot syndrome associated with docetaxel treatment. Acta Oncol. 2011; 51(4):554-6. DOI: 10.3109/0284186X.2011.636755. View

Schlapbach C, Zawodniak A, Irla N, Adam J, Hunger R, Yerly D . NKp46+ cells express granulysin in multiple cutaneous adverse drug reactions. Allergy. 2011; 66(11):1469-76. DOI: 10.1111/j.1398-9995.2011.02677.x. View

Hudis C . The current state of adjuvant therapy for breast cancer: focus on paclitaxel. Semin Oncol. 1999; 26(1 Suppl 2):1-5. View

Roujeau J . Immune mechanisms in drug allergy. Allergol Int. 2006; 55(1):27-33. DOI: 10.2332/allergolint.55.27. View

Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C . Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016; 17(3):345-356. DOI: 10.1016/S1470-2045(15)00542-2. View

Liu M, Liu S, Yang L, Wang S . Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021; 21(1):118. PMC: 7863369. DOI: 10.1186/s12885-021-07831-7. View

Chen Q, Xu S, Liu S, Wang Y, Liu G . Emerging nanomedicines of paclitaxel for cancer treatment. J Control Release. 2022; 342:280-294. DOI: 10.1016/j.jconrel.2022.01.010. View

Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N . Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017; 2(4):277-287. DOI: 10.1016/S2468-1253(16)30219-9. View

10.

Gershenson D, Miller A, Brady W, Paul J, Carty K, Rodgers W . Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022; 399(10324):541-553. PMC: 8819271. DOI: 10.1016/S0140-6736(21)02175-9. View

11.

Rosenberg S, ONeill A, Sepucha K, Miller K, Dang C, Northfelt D . Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer. JAMA Netw Open. 2022; 5(2):e220254. PMC: 8886546. DOI: 10.1001/jamanetworkopen.2022.0254. View

12.

Taylor C, Meisel J, Kalinsky K . Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?. Ther Adv Med Oncol. 2022; 14:17588359221084769. PMC: 8958684. DOI: 10.1177/17588359221084769. View

13.

. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020; 70(4):313. DOI: 10.3322/caac.21609. View

14.

Zong Y, Wu J, Shen K . Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis. Oncotarget. 2017; 8(10):17360-17372. PMC: 5370046. DOI: 10.18632/oncotarget.14477. View

15.

de Leon M, Bolla S, Greene B, Hutchinson L, Del Priore G . Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel. Gynecol Oncol Case Rep. 2013; 5:70-1. PMC: 3862232. DOI: 10.1016/j.gynor.2013.05.003. View

16.

Lenz H . Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007; 12(5):601-9. DOI: 10.1634/theoncologist.12-5-601. View

17.

de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

18.

Harris C, Wang D, Carulli A . Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature. J Oncol Pharm Pract. 2013; 20(1):73-80. DOI: 10.1177/1078155213475466. View

19.

Huang L, Chen S, Yao L, Liu G, Wu J, Shao Z . Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer. Int J Nanomedicine. 2015; 10:1969-75. PMC: 4362893. DOI: 10.2147/IJN.S77000. View

20.

Sibaud V, LeBoeuf N, Roche H, Belum V, Gladieff L, Deslandres M . Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016; 26(5):427-443. PMC: 5526115. DOI: 10.1684/ejd.2016.2833. View